Joined: 1 Jul 05
The IPD is excited to announce it's first designed protein medicine with full approval abroad.
Congrats and thank you to all Rosetta@home contributors! The computing you have provided has greatly aided in de novo protein design challenges such as vaccine development leading to breakthroughs like this.
For more information you can visit the IPD vaccine news post.
A video is also available here.
From the IPD news site:
• Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s
• The protein-based vaccine, now called SKYCovione, does not require deep freezing
• University of Washington to waive royalty fees for the duration of the pandemic
• South Korea to purchase 10 million doses for domestic use
A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.
SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.
The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited.
“We know more than two billion people worldwide have not received a single dose of vaccine,” said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. “If our vaccine is distributed through COVAX, it will allow it to reach people who need access.”
The University of Washington is licensing the vaccine technology royalty-free for the duration of the pandemic.
Congrats and thank you again to all R@h contributors!
Joined: 2 Jan 07
Nice to know it is working
I wonder if this was through Python tasks or Rosetta 4.2
Joined: 11 Feb 08
Nice to know it is working
The first paper in the development of this vaccine was sent in August 2020, revised in Oct 20 and published Oct 31 2020 at Cell all of which is before the results of CASP were published, so there was no Alphafold, Rosettafold nor VBox versions of Rosetta to the best of my memory, unless someone corrects me.
The way I remember things going, all the developments in Rosetta were rolled up and released end March/early April 2020 for us to work on and whatever they asked us to process would reasonably have contributed to this outcome.
I assume we all received an email from UW with this news on 30th June, to which I replied requesting a post to this forum.
I don't know whether this post responds to my request, but I'm very glad they did so
Edit: the email received may only have gone out to people who've made donations to UW rather than all Rosetta users
©2022 University of Washington